This page contains a Flash digital edition of a book.
Research Article Yang, Kernstock, Simmons & Alak


Table 2. Quantitative features of ELISA plates and magnetic beads for protein therapeutic ASP2409. Platform


Cost (US$/96-well plate)†


GBO plate NIA plate MA plate


0.5 2


30 Magnetic beads 250 Calibration curve


Serum sample volume (μl)


y = 0.00411x + 0.00425 100 y = 0.00412x + 0.000976 100 y = 0.00161x + 0.00302 100 y = 0.00398x + 0.00542 200


†The cost was calculated based on the current market price and the assay setting. GBO: Unmodified; MA: Maleic anhydride-activated; NIA: Nunc®


immobilization capacity for CD86 protein could be roughly estimated as 4.8 μg/well. Based on this esti- mate, immobilization capacity for the three plates was experimentally investigated with the protein varying from 0.5 to 20 μg/well using the optimal immobiliza- tion conditions established above and 200 μl of 100 μg/ml ASP2409 in human serum as a probe. Although the absolute responses to ASP2409 were varied among


A


100 80 60 40 20 0


6.51 Immobilizer™ Amino.


MA, NIA and GBO plates, they all showed a similar trend in immobilization capacity where the responses reached the plateau roughly between 3 to 10 μg of the capture protein, CD86. Therefore, 3 μg of CD86 was used in the study. According to the product information, 1 mg of


Tosylactivated beads typically binds 1–10 μg of tar- get protein, but varies from application to application.


C


100 120


6.25


02 4 3.21


B


100 80 60 40 20


1.59 0 0


24 68 Time (min)


4.35 0 68 Time (min) 6.49 D


100 150 200


7.22 5.24 3.1 4.578 0


02 46 8 Time (min)


Figure 2. Multiple reaction monitoring chromatograms at LLOQ for (A) unmodified plate (5 ng/ml), (B) maleic anhydride-activated plate (2 ng/ml), (C) Nunc®


Immobilizer™ Amino Plate (5 ng/ml), (D) magnetic beads


(10 ng/ml), and at ULOQ for (E) unmodified plate plate (850 ng/ml), (F) maleic anhydride-activated plate (100 ng/ml), (G) Nunc®


Immobilizer™ Amino Plate (1000 ng/ml) and (H) magnetic beads (1000 ng/ml). 312 Bioanalysis (2015) 7(3) future science group 8.50 8.86 50 0 2 4 6 Time (min) 6.39 8 8.00 8.52


80 60 40 20


6.51


Linear range (ng/ml)


5.00–850.00 5.00–1000.00 2.00–100.00


10.00–1000.00 r


0.9939 0.9945 0.9927 0.9934


7.16 8.87 0.861.70 3.23 4.77 5.24


4.22 5.16 6.27 7.08 8.81


Intensity (cps)


Intensity (cps)


Intensity (cps)


Intensity (cps)


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122  |  Page 123  |  Page 124  |  Page 125  |  Page 126  |  Page 127  |  Page 128  |  Page 129  |  Page 130  |  Page 131  |  Page 132  |  Page 133  |  Page 134  |  Page 135  |  Page 136  |  Page 137  |  Page 138  |  Page 139  |  Page 140  |  Page 141  |  Page 142  |  Page 143  |  Page 144  |  Page 145  |  Page 146  |  Page 147  |  Page 148  |  Page 149  |  Page 150  |  Page 151  |  Page 152  |  Page 153  |  Page 154